574 related articles for article (PubMed ID: 15368653)
21. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
22. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
23. International differences in drug prices.
Wagner JL; McCarthy E
Annu Rev Public Health; 2004; 25():475-95. PubMed ID: 15015931
[TBL] [Abstract][Full Text] [Related]
24. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
25. International prices and availability of pharmaceuticals in 2005.
Danzon PM; Furukawa MF
Health Aff (Millwood); 2008; 27(1):221-33. PubMed ID: 18180499
[TBL] [Abstract][Full Text] [Related]
26. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
Academy of Managed Care Pharmacy
J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
[TBL] [Abstract][Full Text] [Related]
27. Projecting future drug expenditures--1999.
Mehl B; Santell JP
Am J Health Syst Pharm; 1999 Jan; 56(1):31-9. PubMed ID: 10048877
[TBL] [Abstract][Full Text] [Related]
28. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
29. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
30. Projecting future drug expenditures--1993.
Santell JP
Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
[TBL] [Abstract][Full Text] [Related]
31. The effects of competition on prescription-drug-product substitution.
Kralewski JE; Pitt L; Dowd B
N Engl J Med; 1983 Jul; 309(4):213-6. PubMed ID: 6866035
[TBL] [Abstract][Full Text] [Related]
32. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
Rostron A
Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
[TBL] [Abstract][Full Text] [Related]
33. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
[TBL] [Abstract][Full Text] [Related]
34. Price indexes for pharmaceuticals used by the elderly.
Thomas J; Schondelmeyer S
Health Care Financ Rev; 1992; 14(1):91-105. PubMed ID: 10124442
[TBL] [Abstract][Full Text] [Related]
35. Medicare prescription drug cards: effectiveness for patients with glaucoma.
Mahadevia AA; Nundy S; Frick KD; Jampel HD
Arch Ophthalmol; 2006 Aug; 124(8):1175-9. PubMed ID: 16908821
[TBL] [Abstract][Full Text] [Related]
36. Should drug prices be negotiated under part D of Medicare? And if so, how?
Frank RG; Newhouse JP
Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
[TBL] [Abstract][Full Text] [Related]
37. Savings from drug discount cards: relief for Medicare beneficiaries?
Cubanski J; Frank RG; Epstein AM
Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-198-209. PubMed ID: 15451980
[TBL] [Abstract][Full Text] [Related]
38. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
[TBL] [Abstract][Full Text] [Related]
39. Medicare program; manufacturer submission of manufacturer's average sales price (ASP) data for Medicare Part B drugs and biologicals. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2004 Apr; 69(66):17935-41. PubMed ID: 15068020
[TBL] [Abstract][Full Text] [Related]
40. After years of steady growth, winds of restraint blowing on prescription-drug industry.
Robinson A
CMAJ; 1995 Jul; 153(1):85-8. PubMed ID: 7796380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
